Alexandria Venture Investments
Funding rounds backed by Alexandria Venture Investments.
- Funding disclosed in full
- $635M
- Median round
- $48.5M
- Rounds in calculation
- 10
| Company | Round | Market | Investors | Announced | Details |
|---|---|---|---|---|---|
| Leal Therapeutics Develops neuro-metabolic therapeutics for schizophrenia and ALS | $30MSeries A | BiotechUnited States | |||
| Khartis Therapeutics Develops oral small molecule therapies for immunological and chronic diseases | $50MSeries B | BiotechUnited States | |||
| Vedana Therapeutics Develops next-generation therapies for migraine prevention | $46MSeries A | BiotechUnited States | |||
| SonoThera Develops ultrasound-mediated nonviral genetic medicines | $125MSeries B | BiotechUnited States | 16 participantsAlexandria Venture InvestmentsARCH Venture PartnersARK InvestCureDuchenne VenturesDuquesne Family OfficeIllumina VenturesJohnson & Johnson Innovation – JJDCLeaps by BayerMedical Excellence CapitalOtsuka PharmaceuticalRA CapitalSymBiosisUCB Ventures SAVertex Ventures HCVida VenturesVivo Capital | ||
| CREATE Medicines Develops in vivo immune programming platform for scalable, repeat-dose immunotherapies | $122MSeries B | BiotechUnited States | |||
| Fathom Therapeutics Uses quantum chemistry and AI to design novel drug molecules | $47MSeries A | BiotechUnited States | |||
| Alloy Therapeutics Provides AI-powered platforms and integrated services for drug discovery and development | $40MSeries E | BiotechUnited States | |||
| Ten63 Therapeutics Develops AI-driven drug discovery platform for first- and best-in-class therapeutics | $45MStrategic | AIUnited States | |||
| TRex Bio Develops precision immunoregulatory medicines based on tissue Treg biology | $50MUndisclosed | BiotechUnited States | |||
| Proxima Develops AI-driven drug discovery for proximity therapeutics | $80MUndisclosed | BiotechUnited States |